RIFAPENTINE
MACLEODS PHARMS · RIFAPENTINE
Open FDA's page for this record- Application number
- ANDA217042
- Sponsor name
- MACLEODS PHARMS
- Submissions
- Submission type
- ORIG
- Submission number
- 1
- Submission status
- AP
- Submission status date
- 20260623
- Review priority
- STANDARD
- Submission class code
- UNKNOWN
- Products
- Product number
- 001
- Reference drug
- No
- Brand name
- RIFAPENTINE
- Reference standard
- No
- Dosage form
- TABLET
- Route
- ORAL
- Marketing status
- Prescription
- Te code
- AB
- Active ingredients
- Name
- RIFAPENTINE
- Strength
- 150MG
- Harmonized identifiers (openFDA)
- Application number
- ANDA217042
- Brand name
- RIFAPENTINE
- Generic name
- RIFAPENTINE
- Manufacturer name
- Macleods Pharmaceuticals Limited
- Product NDC
- 33342-599
- Product type
- HUMAN PRESCRIPTION DRUG
- Route
- ORAL
- Substance name
- RIFAPENTINE
- RxCUI
- 242671
- SPL ID
- f95d726e-5a09-48dd-b719-e4400fb91c8f
- SPL set ID
- f95d726e-5a09-48dd-b719-e4400fb91c8f
- Package NDC
- 33342-599-20, 33342-599-54
- Nui
- N0000175501, M0019113
- Pharm class epc
- Rifamycin Antimycobacterial [EPC]
- Pharm class cs
- Rifamycins [CS]
- UNII
- XJM390A33U
